Finding Clues in Genes of ‘Exceptional Responders’
Physician-scientist David Solit was interviewed about exceptional responders, patients who defy all expectations by responding dramatically to a drug t...
Event
A Sneak Preview of Our Annual “Major Trends” Seminar Live Webcast
Every year, MSK gives high school students and their teachers the opportunity to learn about cutting-edge biomedical research from our scientists.
Feature
Memorial Sloan Kettering Transforms Cancer Research and Care Delivery
Memorial Sloan Kettering’s vision is nothing less than to revolutionize the treatment of cancer. Learn about some of the ways we’re doing it.
Cancer ‘Miracle’ Patients Studied Anew for Disease Clues
Physician-scientist David Solit discussed the use of sophisticated DNA sequencing technology to determine why some patients have exceptional responses ...
Announcement
Bold Initiative to Transform Cancer Care Established with a $100 Million Gift
With the creation of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering sets out to deliver on the promise of personalized medicine by creating better treatment options for all people with cancer.
Profile
At Work: Physician-Scientist David Solit
David Solit, Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, discusses how working with cancer patients drives him to develop more-effective, personalized cancer treatments.
Seeking Medical Clues From the 'Super Responder'
Physician-scientist David Solit commented on exceptional responders, patients who respond to treatments when others typically do not....
Looking for Lessons in Cancer's 'Miracle' Responders
Cancer researcher David Solit was profiled about his research to uncover why certain patients respond well to drugs that did not help others....
Feature
Starr Foundation Renews Gifts for Cancer Consortium and Stem Cell Research Initiative
Research at Memorial Sloan Kettering will benefit from renewed support for The Starr Cancer Consortium and the Tri-Institutional Stem Cell Initiative totaling $105 million.
Study Reveals How Some Skin Tumors May Evade New Therapy
Research led by investigators at Memorial Sloan Kettering has identified a previously unknown mechanism of resistance to the newly approved melanoma drug vemurafenib.
Honors
Memorial Sloan Kettering Researchers Appointed to Stand Up To Cancer Melanoma “Dream Team”
Five Memorial Sloan Kettering scientists have been appointed to a new research team dedicated to identifying targets for therapies to treat a certain form of melanoma.
Media Advisory
Researchers Discover Why New Melanoma Drug Stops Working
Research led by investigators at Memorial Sloan Kettering has identified a previously unknown mechanism of resistance to the newly approved melanoma drug, vemurafenib.
Genome Sequencing Clears Up a Cancer Medical Mystery
Cancer researcher and Human Oncology and Pathogenesis Program member David Solit spoke about a study he led that sequenced the entire genome of a patie...
In the Clinic
Prestigious Grant Bolsters Bladder Cancer Research at MSK
A prominent research grant will enable MSK doctors and scientists to advance the treatment of bladder cancer.
